Actively Recruiting
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
Led by Shanghai Jiaolian Drug Research and Development Co., Ltd · Updated on 2026-05-05
90
Participants Needed
17
Research Sites
129 weeks
Total Duration
On this page
Sponsors
S
Shanghai Jiaolian Drug Research and Development Co., Ltd
Lead Sponsor
S
Shanghai Pharmaceuticals Holding Co., Ltd
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.
CONDITIONS
Official Title
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female subjects who voluntarily agree to participate and sign informed consent
- Diagnosis of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer confirmed by tissue examination
- Cancer must be platinum-resistant and recurrent
- ECOG performance status of 0 or 1
- Expected survival longer than 12 weeks
- At least one measurable tumor lesion
- Normal major organ function
- Fertile participants agree to use reliable contraception from consent signing to 6 months after last dose
You will not qualify if you...
- Prior prescribed treatment for this cancer
- Current use of anti-tumor traditional Chinese patent medicines at consent signing
- Known metastases in the central nervous system or multiple bone metastases
- Clinical symptoms of pleural effusion, pericardial effusion, or ascites needing drainage before randomization, or had drainage within 2 weeks prior
- History of other cancers within 5 years before consent
- Presence of prescribed cardiovascular diseases
- Infections requiring intravenous antibiotics within 2 weeks before randomization
- Severe lung disease before randomization
- Peripheral nerve toxicity greater than grade 2 or other reversible toxicity greater than grade 1 from prior treatment
- Surgery within 28 days prior to randomization without recovery from adverse effects
- Participation in another clinical trial within 30 days before randomization involving unmarketed investigational drugs
- Known allergy to B013 or paclitaxel components
- History of substance abuse, alcohol or drug use, neurological or psychiatric disorders
- Pregnant or breastfeeding females
- Other conditions judged unsuitable by researchers or sponsors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 17 locations
1
Beijing Cancer Hospital
Beijing, China
Actively Recruiting
2
The First Affiliated Hospital of Bengbu Medical University
Bengbu, China
Actively Recruiting
3
XiangYa Hospital CentralSouth University
Changsha, China
Actively Recruiting
4
Fujian Cancer Hospital
Fuzhou, China
Actively Recruiting
5
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China
Actively Recruiting
6
Cancer Hospital of Shandong First Medical University
Jinan, China
Actively Recruiting
7
Qilu Hospital of Shandong University
Jinan, China
Actively Recruiting
8
Yunnan Cancer Hospital
Kunming, China
Actively Recruiting
9
Guangxi Medical University Cancer Hospital
Nanning, China
Actively Recruiting
10
Fudan University Shanghai Cancer center
Shanghai, China
Actively Recruiting
11
The Obstetrics & Gynecology Hospital of Fudan University
Shanghai, China
Actively Recruiting
12
The Second Hospital of Hebei Medical University
Shijiazhuang, China
Actively Recruiting
13
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Actively Recruiting
14
Shananxi Provincial Cancer Hospital
Xi'an, China
Actively Recruiting
15
The First Affiliated Hospital of Xiamen University
Xiamen, China
Actively Recruiting
16
Yibin city second people's Hospital
Yibin, China
Actively Recruiting
17
Henan Cancer Hospital
Zhengzhou, China
Actively Recruiting
Research Team
X
Xiaohua Wu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here